Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: 100.70%
|Next Earnings Date:May 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record revenue growth, innovative biomarker launches, improved gross margins, and operational enhancements. Despite challenges in testing volume and physician attrition, the overall sentiment is positive due to strong financial performance and strategic advancements.Company Guidance
In the Exagen Inc. Fourth Quarter 2024 Earnings Conference Call, significant guidance was provided for the year ahead. Exagen closed 2024 with a record total revenue of $55.6 million, driven by an improved average selling price (ASP) of $411 for AVISE CTD, marking a $75 increase per test over 2023. The company narrowed its adjusted EBITDA loss to approximately $10 million, with gross margins expanding over 300 basis points to nearly 60%. In 2025, Exagen expects revenue growth through ASP expansion and additional sales territories, aiming for positive adjusted EBITDA by Q4. The launch of new biomarkers in January 2025 added approximately $90 in incremental revenue per test, which is expected to further enhance gross margins. Looking ahead, Exagen anticipates achieving at least $14.5 million in Q1 2025 revenue and targets sustainable free cash flow positivity by 2026, with plans for additional product launches and strategic sales expansion to drive growth.Record Revenue Growth
Exagen Inc. achieved a record total revenue of $55.6 million for 2024, marking a 6% increase from 2023. This was primarily driven by improvements in reimbursement and a focus on profitability.
Innovative Biomarker Launch
Exagen launched new biomarkers for the AVISE CTD test, including RA33 and T cell markers, enhancing diagnostic capabilities for rheumatoid arthritis and lupus. These markers have been well-received and are expected to increase patient care impact and revenue.
Improved Gross Margins
Gross margins expanded by over 300 basis points, approaching 60% for the full year 2024, attributed to increased ASP and operational efficiency.
Operational and Cultural Improvements
The company has reduced losses by over 70%, improved company culture by reducing voluntary turnover significantly, and enhanced overall team alignment and motivation.
Positive Adjusted EBITDA Outlook
The company anticipates being adjusted EBITDA positive in the fourth quarter of 2025, marking a key milestone in its financial turnaround.
---
XGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $2.85 | $3.37 | +18.25% |
| Nov 12, 2024 | $2.97 | $2.79 | -6.06% |
| Aug 05, 2024 | $2.04 | $2.40 | +17.65% |
| May 13, 2024 | $1.57 | $1.64 | +4.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Exagen Inc (XGN) report earnings?
Exagen Inc (XGN) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Exagen Inc (XGN) earnings time?
Exagen Inc (XGN) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XGN EPS forecast?
XGN EPS forecast for the fiscal quarter 2025 (Q1) is -0.22.
---